https://www.thebodypro.com/category/prep-hiv-pre-exposure-prophylasxis/tag/research

The Latest

Scientist holding slide with blood sample in lab

This Week in HIV Research: U=U Grows Ever Stronger

Oct. 10, 2019: Long-term viral suppression = zero genital tract shedding among women; HIV treatment initiation and sexual risk among MSM; PrEP interest vs. uptake among trans women of color; polypharmacy among people living with HIV.

people in a doctor's office waiting room

This Week in HIV Research: The Reality of Disparity

Sept. 26, 2019: Racial disparities in the PrEP continuum; HIV and ocular syphilis; Kaposi sarcoma among people with well-suppressed HIV; modifiable risk factors in the management of chronic kidney disease.

woman with doctor looking at prescription bottle

This Week in HIV Research: Every Prescription Can Use a Good Steward

Sept. 19, 2019: HIV antiretroviral stewardship plans in hospitals can save money -- and lives; demographic correlates of PrEP interruption; HIV and atrial fibrillation risk; cytopenias common, despite viral suppression.

woman's hand dangling keys

This Week in HIV Research: New Keys to the Care Continuum

Sept. 12, 2019: Better virologic outcomes at coordinated walk-in facilities offering incentives; same-day PrEP initiation at STD clinics; U=U and "low drug regimens"; adherence trends among perinatally infected adolescents.

young woman taking blue pill

Four PrEP Studies Address Challenges and Best Practices for Uptake and Retention

Four recent studies in JAIDS chiefly focused on PrEP provision to cisgender women and gay and bisexual men.

person rolling joint, focus on hands, cannabis on table

This Week in HIV Research: Sex, Drugs, and Broken Bones

Aug. 8, 2019: Casual sex partners increase among U.S. MSM; why some MSM undervalue PrEP; proteinuria prevalence and fracture risk; cannabis, cocaine, and inflammation in people living with HIV.

Christoph D. Spinner

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

Ivana Beesham

Experts Flummoxed By Conflicting New Data on STIs, HIV, and Long-Term Contraception in Sub-Saharan Africa

ECHO trial results and follow-up studies find unexpectedly low rates of some STIs among users of certain long-term hormonal contraceptives. They also find high HIV rates (unrelated to the contraceptives) that suggest considerable value for PrEP integration.

couple on the boardwalk surrounded by seagulls

This Week in HIV Research: When STIs Flock Together

July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.

man getting vaccine

Large Scale HIV Vaccine Trial Announced, But PrEP May Challenge Enrollment

Will potential study participants choose a vaccine trial over getting access to PrEP?